Serotonin SyndromeMoclobemideSerotoninClinical Trials, Phase IV as TopicSerotonin AgentsMuscle HypertoniaMyoclonusChlorpheniramineSerotonin Uptake InhibitorsMonoamine Oxidase InhibitorsDrug OverdosePsychomotor AgitationReflex, AbnormalAntitussive AgentsDextromethorphanAcetamidesSweatingOxazolidinonesSerotonin Plasma Membrane Transport ProteinsProduct Surveillance, PostmarketingReceptors, SerotoninTremorReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT1ASerotonin AntagonistsReceptor, Serotonin, 5-HT2CDiagnostic Tests, RoutineReceptor, Serotonin, 5-HT2BReceptors, Serotonin, 5-HT2Receptor, Serotonin, 5-HT1BSerotonin Receptor AgonistsReceptors, Serotonin, 5-HT1Serotonin 5-HT2 Receptor AntagonistsToxicity TestsReceptors, Serotonin, 5-HT3Serotonin 5-HT2 Receptor AgonistsTryptophan HydroxylaseSerotonin 5-HT1 Receptor AgonistsReceptors, Serotonin, 5-HT4Serotonin 5-HT1 Receptor AntagonistsToxicity Tests, AcuteHydroxyindoleacetic AcidFluoxetineDose-Response Relationship, DrugCitalopramSerotonergic NeuronsKetanserin5-HydroxytryptophanRaphe NucleiParoxetine8-Hydroxy-2-(di-n-propylamino)tetralinMethysergideFenclonineReceptor, Serotonin, 5-HT1D5,7-DihydroxytryptamineBiogenic MonoaminesSerotonin 5-HT3 Receptor AntagonistsLethal Dose 50Rats, Sprague-DawleyDrug Administration ScheduleAntidepressive AgentsAntineoplastic Combined Chemotherapy ProtocolsDopamineBrainToxicity Tests, ChronicFenfluramineTime FactorsN-Methyl-3,4-methylenedioxyamphetamineAntidepressive Agents, Second-GenerationCinanserinAntineoplastic AgentsTreatment OutcomeMembrane Transport ProteinsNeuronsAntidepressive Agents, TricyclicMonoamine OxidaseAmphetaminesBehavior, AnimalFluvoxamineTryptaminesPiperazinesDrug InteractionsCyproheptadineLysergic Acid DiethylamideTryptophanBlood PlateletsImipramineClomipramineBiogenic AminesInfusions, IntravenousSertralineNerve Tissue ProteinsCisplatinNorepinephrine Plasma Membrane Transport ProteinsCell SurvivalRats, WistarOctopamineAdministration, OralMethiothepinp-Chloroamphetamine